ALEXANDERIA, VA USA (Press Release) - May 23, 2012
−June 1-4: Onsite Press Conferences in Chicago−
The American Society of Clinical Oncology (ASCO) today announced the studies to be featured in the 2012 ASCO Annual Meeting press program. The press program will include new advances in precision cancer medicine and targeted therapy; major trial results for ovarian, breast, brain, lymphoma and other cancers; and significant advances in supportive care and patient quality of life.
The ASCO Annual Meeting will take place in Chicago, Friday, June 1 – Tuesday, June 5 and attract more than 30,000 oncology professionals from around the globe. This year more than 4,500 abstracts will be presented or published at the Meeting, covering the latest advances in clinical cancer research and patient care, reinforcing the theme of this year’s meeting, "Collaborating to Conquer Cancer."
The majority of Annual Meeting abstracts were publicly posted on abstract.asco.org on Wednesday, May 16 at 6:00 PM EDT. ASCO hosted an embargoed presscast for media at 12:00 noon EDT that day to highlight several noteworthy studies. Plenary, Late-breaking and Clinical Review abstracts were released on site at the meeting. The full media and embargo policies and the press program schedule-at-a-glance are available on ASCO’s Annual Meeting Media Resource Center, including detailed information about updates to the embargo policies and timeline for Plenary, Late-Breaking and Clinical Review abstracts.
ON SITE: HIGHLIGHTED RESEARCH
ASCO will hold daily, embargoed press conferences to highlight research from the following day’s conference sessions. ASCO may hold additional press conferences on various topics throughout the meeting. Press briefings will highlight the following research:
Friday, June 1, 3:00-4:00 PM CDT(Embargoed until June 2 at 12:01 AM EDT):
- The first randomized, Phase III trial of bevacizumab (Avastin) plus chemotherapy for platinum-resistant recurrent ovarian cancer
- Use of a new anti-PD1 targeted immunotherapy (BMS-936558) to treat melanoma, prostate, lung and kidney cancers
- A comparison of treatment outcomes in adolescent and young adult patients, versus younger patients, with high risk acute lymphoblastic leukemia
- A novel approach that considers patient preferences for renal cancer treatments based on quality of life factors
Saturday, June 2, 11:00 AM-12:00 noon CDT(Embargoed until June 3 at 12:01 AM EDT):
- Intermittent versus continuous hormonal therapy in men with advanced prostate cancer (Plenary)
- Use of rituximab (Rituxan) and bendamustine, versus “CHOP” chemotherapy, in indolent (slow-growing) or mantle cell lymphomas (Plenary)
- Use of the novel “antibody-drug conjugate” trastuzumab emtansine in certain patients with HER2-positive breast cancer (Plenary)
- Impact of chemotherapy and radiation – and genetic predictors of treatment response – in patients with oligodendrioglial (brain) tumors (Plenary)
- Phase III data on the use bevacizumab (Avastin) with both first- and second-line chemotherapy in advanced colorectal cancer
- New survey data on cancer patients’ decision-making about clinical trial participation
Sunday, June 3, 9:00-10:00 AM CDT(Embargoed until June 4 at 12:01 AM EDT):
- Use of the experimental drug afatinib in the largest Phase III trial to date of patients with advanced, EGFR-positive lung cancer
- A comparison of the MEK inhibitor trametinib to standard chemotherapy in patients with advanced melanoma
- Use of the BRAF inhibitor dabrafenib with standard chemotherapy in patients with advanced melanoma that harbors the V600 BRAF mutation
- Use of the targeted drug regorafenib in patients with GIST that progressed after prior therapies
- Feasibility of routine genomic testing of lung tumor samples in a clinic setting to guide choice of treatments
Sunday, June 3, 11:00 AM-12:00 noon CDT(Embargoed until June 4 at 12:01 AM EDT):
- A comparison of newer treatment options to long-standing paclitaxel therapy in patients with locally recurrent or metastatic breast cancer
- Long-term risk of breast cancer among childhood cancer survivors treated with chest radiation
- Phase III data on a new treatment for chemotherapy-induced peripheral neuropathy, a common and debilitating side effect of certain cancer therapies
- Quality of family cancer history-taking and referral for genetic counseling and testing in U.S. oncology practices, based on ASCO’s QOPI quality program
MEDIA RESOURCES AND FACILITIES
- Media Registration: To register for the embargoed May 16 Presscast or to attend the ASCO Annual Meeting, please visit ASCO’s Media Headquarters at http://mediahq.asco.org. Registration must be completed no later than May 14 to participate in the embargoed May 16 Presscast. Annual Meeting pre-registration for U.S. and international journalists is required and must be completed by Friday, May 18, 2012.
- Online Resources: A full suite of resources for media are available at the Annual Meeting Media Resource Center
- On-site Resources: A full-service Press Room will provide wireless Internet, telephones, fax, scanner, printers, and limited computer workstations with Internet access. A limited number of private interview rooms will also be available. Leading cancer experts will be available to speak with members of the press upon request.
- Photos from the ASCO Annual Meeting and press briefings will be available through ASCO’s online Photo Gallery each day of the Meeting. Media requests for specific photos are welcome and accommodated to the greatest degree possible.
- Shuttle service between Annual Meeting hotels and the convention center will be available.
- ASCO’s Virtual Meeting will provide online access to all major sessions following the meeting.
- Access to the Virtual Press Room – an online repository of corporate and institutional press materials created by third-party organizations.
- ASCO’s CancerProgress.Net offers a detailed, interactive timeline of advances against 14 of the most common cancers, including several highlighted in the Annual Meeting press program. The site also includes simple, interactive charts on cancer survival, mortality, and incidence, along with historical commentary and other reporting resources.
- Cancer.Net, ASCO’s award-winning patient website, provides comprehensive, doctor-approved information on more than 120 cancer types, together with expert information on cancer treatments, managing side effects and coping with a cancer diagnosis.
About ASCO
The American Society of Clinical Oncology (ASCO) is the world’s leading professional organization representing physicians who care for people with cancer. With more than 30,000 members, ASCO is committed to improving cancer care through scientific meetings, educational programs and peer-reviewed journals. ASCO is supported by its affiliate organization, the Conquer Cancer Foundation, which funds ground-breaking research and programs that make a tangible difference in the lives of people with cancer. For ASCO information and resources, visit www.asco.org. Patient-oriented cancer information is available at www.cancer.net.
The American Society of Clinical Oncology (ASCO)
[ PRESS RELEASE ]